Loading...
Loading...
EQRX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 85.7M |
| Operating I/L | -85.7M |
| Other Income/Expense | 106.4M |
| Interest Income | 0.2M |
| Pretax | 20.7M |
| Income Tax Expense | -212.1M |
| Net Income/Loss | 232.9M |
EQRx, Inc. is a pharmaceutical company focused on developing medicines for oncology and immune-inflammatory diseases. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an EGFR inhibitor for EGFR-mutated non-small cell lung cancer, and Sugemalimab, an anti-PD-L1 antibody for Stage III and Stage IV NSCLC. Other pipeline assets include Lerociclib, a small molecule CDK 4/6 inhibitor in Phase II trials for metastatic breast cancer; EQ176, an anti-PD-1 antibody in Phase III trials for primary liver cancer; and EQ121, a selective JAK-1 inhibitor in various Phase I trials.
